Skip to main content

Casdin Capital — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

95
Companies
$8.1B
Total invested
$93.1M
Avg. check
22
Industries
Biotechnology 20Health Care 11Medical 5Genetics 4Therapeutics 4Life Science 3+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7395 of 95
InnoSIGN
March 2022

InnoSIGN is a manufacturer of precision medicine for diagnostics and drug development applications.

Biotechnology · Eindhoven$8.1M Series A
Creyon Bio
March 2022

Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.

Biotechnology · San Diego$40.0M Series A
Basilard BioTech
February 2022

Basilard BioTech features a technology platform that transforms the rapidly growing cell-based therapies market.

Biopharma · CaliforniaSeed
Depixus
December 2021

Depixus are pioneering the development of MAGNA, a novel genetic analysis technology for decoding the dynamic genome.

Biotechnology · Paris$34.5M Series A
Exai Bio
December 2021

Exai Bio is an orphan non-coding RNAs and AI-based liquid biopsy company.

Biotechnology · Palo Alto$67.5M Series A
908 Devices
November 2021

908devices manufactures battery-operated, hand-held chemical detection tools used in mass spectrometry.

Battery · Boston$101.0M Post Ipo Equity
Exo Therapeutics
October 2021

Exo Therapeutics is a small molecule drug discovery and development company.

Biotechnology · Cambridge$78.0M Series B
Zentera Therapeutics
August 2021

Zentera Therapeutics is a biopharmaceutical company.

Biotechnology · Shanghai$75.0M Series B
Mnemo Therapeutics
June 2021

Mnemo Therapeutics specializes in biotechnology and life science.

Biotechnology · Paris$90.0M Series A
Vedere Bio ll
May 2021

Vedere Bio is developing gene therapy products to restore functional vision to patients who have suffered vision loss.

Biotechnology · Cambridge$77.0M Series A
Magenta Therapeutics
May 2021

Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.

Biotechnology · Cambridge$86.4M Post Ipo Equity
Apton Biosystems
April 2021

Apton Biosystems develops an optical system designed for sequencing and protein detection.

Biotechnology · Pleasanton$24.6M Series A
C2i Genomics
April 2021

C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations.

Genetics · New York$100.0M Series B
SeQure Dx
April 2021

SeQure Dx provides safety data for on and off-target CRISPR gene editing therapies

Biopharma · Waltham$17.5M Series A
Imagen
February 2021

Imagen is a healthcare organization that provides onsite and diagnostic solutions to maximize clinical outcomes and patient satisfaction.

Artificial Intelligence (AI) · New York$75.0M Series C
Faze Medicines
December 2020

Faze Medicines is a biotechnology company.

Biotechnology · Cambridge$81.0M Series A
PanThera CryoSolutions Inc.
December 2020

PanThera CryoSolutions designs and manufactures cryopreservation solutions for cells, tissues, and organs.

Health Care · Edmonton$2.0M Series A
PACT Pharma
January 2020

Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.

Biotechnology · Hayward$75.0M Series C
Sexton Biotechnologies
September 2019

Sexton Biotechnologies is a biotechnology company.

Biotechnology · Indianapolis$5.0M Series Unknown
Singular Bio
January 2019

Singular Bio is a privately held company developing single molecule detection technology.

Biotechnology · San Francisco$6.6M Series Unknown
Prominex
September 2018

Prominex is focused on the development and manufacture of molecular diagnostic assays for Point-of-Care (POC) infectious disease testing.

Biotechnology · San Diego$4.0M Series A
Neon Therapeutics
December 2017

NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.

Bioinformatics · Cambridge$36.0M Series B
Foundation Medicine
January 2013

Foundation medicine is a molecular information company developing clinical diagnostic tests that facilitates personalized cancer therapies.

Biotechnology · Cambridge$13.5M Series B

Where Casdin Capital invests

Biotechnology20
Health Care11
Medical5
Genetics4
Therapeutics4
Life Science3

About Casdin Capital's portfolio

How many companies has Casdin Capital invested in?

Casdin Capital has invested in 95 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Casdin Capital invest in?

Casdin Capital's top investment sectors include Biotechnology, Health Care, Medical, Genetics, Therapeutics. The firm invests across 22 different industry categories.

What is Casdin Capital's largest investment?

Among tracked funding rounds, 908 Devices received $101.0M in a Post Ipo Equity round. Casdin Capital's total known invested capital is $8.1B.

What is the average investment size for Casdin Capital?

Casdin Capital's average investment size is $93.1M across its portfolio of 95 companies.

What are Casdin Capital's most recent investments?

Recent Casdin Capital portfolio additions include InnoSIGN, Creyon Bio, Basilard BioTech, Depixus, Exai Bio. These companies were founded in 2020 or later.

Reach the founders behind these 95 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →